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Dendritic release of neurotransmitters 
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Release of neuroactive substances by exocytosis from dendrites is 
surprisingly widespread and is not confined to a particular class of 
transmitters: it occurs in multiple brain regions, and includes a range of 
neuropeptides, classical neurotransmitters and signaling molecules 
such as nitric oxide, carbon monoxide, ATP and arachidonic acid. This 
review is focused on hypothalamic neuroendocrine cells that release 
vasopressin and oxytocin and midbrain neurons that release dopamine. 
For these two model systems, the stimuli, mechanisms and 
physiological functions of dendritic release have been explored in 
greater detail than is yet available for other neurons and neuroactive 
substances.  
 
Introduction 
The dendrites of many neural populations transmit information back to 
their synaptic inputs by releasing neuroactive substances (89, 99, 128). 
Indeed, modulation of neuronal function by dendritic transmitter release is a 
widespread phenomenon and is specific neither to a localized part of the brain 
nor to a particular subtype of signalling molecule. In addition to membrane-
permeant substances such as carbon monoxide, arachidonic acid and nitric 
oxide, classical transmitters can be released from dendrites to signal in a 
retrograde fashion. For example, somatodendritic release of dopamine, which 
is the exemplar small molecule transmitter emphasized in this review, 
modulates the firing rate and excitability of midbrain dopamine neurons. In 
addition, the amino acids GABA and glutamate act as retrograde transmitters 
in the olfactory bulb, hippocampus, cortex and cerebellum (90, 119, 226, 266). 
However, the most numerous class of signalling molecules in the brain is the 
neuropeptides and there is ample evidence for their dendritic release. There is 
convincing evidence for somatodendritic release of the neurohypophysial 
peptides, oxytocin and vasopressin, in the hypothalamus (111, 116, 120, 
127), which are the exemplar peptides covered in this this review. Notably, 
there are also reports for this mode of release for other peptides, including 
dynorphin, enkephalin and cholecystokinin (19, 46, 216).   
 
 
The hypothalamo-neurohypophysial peptide system 
Oxytocin and vasopressin (antidiuretic hormone, ADH) enter the 
circulation following exocytotic release from magnocellular neurosecretory 
cells (MCNs), components of hypothalamic supraoptic (SON) and 
paraventricular nuclei (PVN) that project into the posterior pituitary gland. 
Oxytocin is required for milk ejection, and produces uterine contractions, and 
so has a role in parturition and lactation (4, 19, 81, 114, 202), whereas 
vasopressin is involved in the regulation of water excretion and blood 
pressure. In addition, both peptides have effects on behavior (see below). 
Both are released at axonal synapses, but also from the somata and 
dendrites of MCNs (99, 111, 116, 120, 127, 128, 155, 168). The cell bodies 
and dendrites of MCNs form densely packed and homogeneous nuclei, 
whereas their axons project into the posterior pituitary gland. As there is no 
blood-brain barrier in the posterior pituitary, peptide secretion from axons 
swiftly enters the bloodstream. The dendrites of adult rat MCNs are 
characteristically smooth (aspiny), thick and varicose, with little branching, 
and are often associated in bundles (147, 221). Most of the neuropeptides 
expressed in the SON and PVN are stored within MCN dendrites. Dendritic 
release can be studied in these regions by push-pull perfusion or 
microdialysis (150, 256). Importantly, these methods can be used to study 
dendritic release independently of axonal release, because re-entry of 
peripherally released peptide into the brain is prevented by the blood-brain 
barrier.  
 Although the SON contains only MCNs, the PVN contains both MCNs 
and many other morphologically and functionally distinct cell types. 
Parvocellular neurosecretory neurons make axonal contact with the median 
eminence and they release hypophysiotropic hormones that regulate 
functions of the anterior pituitary and the major hypothalamo-pituitary axes. 
Parvocellular preautonomic neurons modulate sympathetic and 
parasympathetic outflow to several organs, including the heart, the peripheral 
vasculature and the kidneys (31, 223, 262), through long descending 
projections into sympathetic and parasympathetic centers in the brainstem 
and spinal cord. Some neurons within the PVN also project into other limbic 
areas, including the central amygdala, and have recently been shown to 
modulate fear-conditioned (103).  
 Because of these features, the PVN is a particularly useful system for 
studying communication within and between different neuronal populations in 
the brain (218, 220), and particularly the role of neuropeptides in this process. 
 
The nigrostriatal and mesolimbic dopamine systems 
Another transmitter system that relies on somatodendritic release is 
dopamine, which is released from midbrain dopamine neurons. Dopamine 
neurons of the substantia nigra pars compacta (SNc) give rise to the 
nigrostriatal dopamine pathway, which is essential for motor learning and 
motor control. Indeed, loss of dopamine in this system impairs neuronal 
output from the basal ganglia (76), leading to the motor impairments that 
characterize Parkinson’s disease (1, 24, 134, 251). In addition, dopamine 
from this pathway, and from the ventral tegmental area (VTA), also in 
midbrain, influences a number of other brain functions including reward, 
emotion, cognition and memory (25, 181, 193).  
 Dopamine neurons of the SNc and VTA send axon projections that 
densely innervate the striatal complex in the forebrain (139): the nigrostriatal 
dopamine pathway projects from the SNc preferentially to the dorsal striatum 
(caudate-putamen, CPu), whereas the mesolimbic dopamine pathway 
projects from the VTA preferentially to the ventral striatum (nucleus 
accumbens, NAc). In addition, VTA dopamine neurons project via the 
mesocortical pathway to the prefrontal cortex, hippocampus and amygdala 
(80, 246).  
 Like that of all catecholamines, the synthesis of dopamine originates 
from the amino acid precursor L-tyrosine, which is transported across the 
blood brain barrier into dopamine neurons. Tyrosine is converted to L-
dihydroxyphenylalanine (L-DOPA) by the rate-limiting enzyme tyrosine 
hydroxylase (TH) and then to dopamine by L-aromatic amino acid 
decarboxylase (Fig. 1B). Notably, unlike many transmitters/neuromodulators 
that are synthesized in the cell body and transported to distant release sites in 
axons, TH protein expression in dopamine neurons can be seen throughout 
the soma, dendrites and axons (254). Moreover, regulation of TH activity by 
phosphorylation occurs in both somatodendtic compartments and terminal 
fields, thereby indicating that dopamine is synthesized locally for either 
somatodendritic or axonal release (209). 
The release of dopamine from axonal sites is fairly well characterized. 
However, dopamine release from the somata and dendrites of midbrain 
dopamine neurons in the SNc and VTA remains incompletely understood, 
despite extensive research over decades (9, 10, 17, 26, 29, 32, 40, 69, 74, 
169, 184, 196, 198). Because the somata and dendrites are intermingled in 
these regions, their individual contributions to dopamine release cannot be 
distinguished easily, so the term “somatodendritic” is used to describe non-
axonal evoked dopamine release in SNc and VTA. Mechanistic studies of 
somatodendritic dopamine release have been conducted primarily in the SNc, 
in which dopamine release is exclusively somatodendritic (95, 249). In 
contrast, the VTA has collaterals from its own axons, as well as from those 
that arise in the SNc (7, 56). 
 
Experimental methods used to study somatodendritic release 
 
Oxytocin and vasopressin 
    Ideally, experimental methods to study somatodendritic release of 
oxytocin and vasopressin should have sufficient resolution to define the 
location and time course of release. Although the number of techniques that 
meet these criteria is limited, the use of hypothalamic explants containing the 
SON, sometimes with the pituitary gland attached (217), has provided insights 
into the regulation of somatodendritic release by steroids, changes in 
intracellular Ca2+ concentrations, the activation of autoreceptors and second 
messenger pathways (33, 105, 121, 129, 204, 206, 252). 
    The most widely used approach is to monitor changes in neuropeptide 
concentrations in the plasma, through the use of sensitive chemical assay 
techniques such as radioimmunoassay (RIA) and enzyme-linked 
immunosorbent assay (ELISA). RIA, in particular, offers the high sensitivity 
required for the quantification of neuropeptides collected in vivo using push-
pull perfusion (110, 150, 160) and microdialysis (98, 256). With these 
methods, samples can be collected from the extracellular space of defined 
brain structures in unrestrained animals, with timescales of minutes to days 
(62, 110, 255). Other in vivo sampling techniques have also been employed, 
including the simultaneous detection of hormones secreted into the blood, 
using specialized microdialysis probes (166) or chronically implanted jugular 
venous catheters (257). In anesthetized animals, simultaneous 
electrophysiological recording has been combined with microdialysis (126). 
Other approaches for measuring neuropeptides in microdialysates 
include immunosensing with microdialysis probes containing antibody-based 
electrodes and capillary liquid chromatography combined with electrospray 
ionization-mass spectrometry (37, 131). Although these techniques have 
comparable sensitivity to that of RIA they have not yet been widely applied. 
 
Dopamine 
 The first studies of somatodendritic dopamine release involved either 
the measurement of 3H-dopamine overflow from in vitro midbrain slices (74) 
or in vivo measurements in midbrain using push-pull perfusion (32, 169). 
Subsequently, microdialysis coupled with electrochemical detection was used 
for in vivo studies of dopamine release (11, 13, 61, 83, 97, 199, 211). The use 
of microdialysis offered the advantage of a separation step, enabling 
dopamine, its metabolites and in some cases other neurotransmitters to be 
assayed simultaneously. A problem with this or any in vivo method, however, 
is that systemically or locally applied drugs may affect regulatory processes, 
which could be mediated by extended pathways; because of this, in vitro cell 
culture preparations and midbrain slices have been used in most recent 
mechanistic studies of somatodendritic dopamine release, with dopamine 
overflow in culture typically measured by HLPC or RIA (70, 143).  
In slices, the approaches primarily used to detect somatodendritic 
dopamine release are fast-scan cyclic voltammetry (FCV) and amperometry 
with carbon-fiber microelectrodes. These methods permit the quantification of 
changes in extracellular dopamine concentration ([DA]o) with high temporal 
and spatial resolution, on scales of milliseconds and micrometers, 
respectively (146, 183). This is crucial for the rapid detection of release 
evoked in small discrete regions of the brain, including the SNc and VTA ((29, 
40, 69, 184, 196, 198). In these methods, the target molecule (dopamine) is 
oxidized at the surface of the carbon-fiber microelectrode with a suitable 
applied potential, and the resulting current, which is directly proportional to the 
rate of oxidation of transmitter molecules, is recorded. With FCV, the applied 
potential is ramped up and down, enabling identification of released dopamine 
from its characteristic voltammogram (26, 196). The release of dopamine can 
also be verified by the effects of pharmacological agents; for example the 
response is increased by inhibitors of the plasma membrane dopamine 
transporter (DAT) (29, 42) and decreased by inhibitors of the vesicular 
monoamine transporter (VMAT2) (198).  
In amperometry, a potential is applied at a constant value that is 
sufficient to oxidize dopamine. This method has been used to examine 
quantal release of dopamine from neuronal somata (91, 102). One drawback 
of voltammetric and amperometric methods is the possibility of signal 
contamination by contributions from other endogenous electroactive 
substances. For example, in FCV studies of somatodendritic dopamine 
release in the substantia nigra of some rodent species, including rats and 
mice, the voltammetric signal is heavily contaminated by locally released 
serotonin (5-hydroxytryptamine, 5-HT). Given that microdialysis studies 
include a chemical separation step, that technique avoids this lack of 
specificity. Interestingly, this is not a concern when detecting dopamine 
release in the VTA because the VTA of mice, rats and guinea pigs lack 5-HT 
innervation and thus the voltammetric signal arises exclusively from dopamine 
(26, 38, 42, 93).  
Most recently, Williams and colleagues applied electrophysiological 
techniques to detect somatodendritic dopamine release. By using whole-cell 
voltage-clamp recording from midbrain dopamine neurons, it is possible to 
record D2 dopamine autoreceptor-dependent inhibitory currents (D2ICs) to 
monitor evoked dopamine release in the SNc and VTA (9, 10, 38, 68, 69).  
 
Vasopressin and oxytocin are released by exocytosis 
    Vasopressin and oxytocin are stored in and released from large 
dense-cored vesicles (LDCVs). Classical morphological evidence for 
somatodendritic release was provided by electron-microscopic studies on 
hypothalamic neurons, which showed LDCVs within the dendrites and somata 
of MCNs, together with omega-shaped fusion profiles at the plasma 
membrane (189). Exocytosis from the dendrites of oxytocin and vasopressin 
neurons was also demonstrated by treatment of hypothalamic tissue with 
tannic acid to fix exocytosed peptide granules (155, 157, 189). Since peptide 
release from MCNs is not restricted to any particular region of the plasma 
membrane (157, 189), regulation of exocytosis may occur simply by 
controlling the access of vesicles to the sites of fusion (151). In classical 
neuroendocrine cells, control of this type is exerted by cytoskeletal elements, 
and such control may also occur in MCNs, as their cell bodies contain an actin 
network proximal to the plasma membrane, usually referred to as cortical F-
actin. In neuroendocrine cells, this network surrounds the secretory vesicles.  
 The actin network undergoes rapid, transient and reversible 
depolymerization during exocytosis, and F-actin is depleted close to fusion 
zones. The cortical F-actin network has long been proposed to restrict the 
movement of secretory vesicles to fusion zones on the plasma membrane 
(57, 245). The subcortical regions of somata and dendrites in MCNs contain 
polymerized F-actin (238, 248), which is rapidly and reversibly depolymerized 
when secretion is stimulated, and drugs that depolymerize F-actin stimulate 
dendritic peptide release. Thus, evoked release of peptides from the dendrites 
requires the depolymerization of F-actin (Fig. 1A) (238). 
    However, although cortical F-actin has historically been viewed as a 
barrier that restricts the movement of LDCVs to the plasma membrane, it 
might also have an enabling role in exocytosis, either by providing ‘tracks’ for 
LDCV movement to fusion zones, or by constraining some components of the 
fusion machinery. This would suggest that during secretion the F-actin 
network is not simply disassembled, but reorganized to allow the access of 
LDCVs to fusion sites and to provide or assemble the molecular machinery 
necessary for membrane fusion and exocytosis (57). In MCNs, F-actin 
remodeling appears to be involved in the trafficking of functionally mature, 
release-competent vesicles to fusion sites, and it may therefore be critical in 
the differential control of release from different parts of the cell. However, in 
contrast to release from neuronal synapses, vesicle fusion in both the 
somata/dendrites and axon terminals in MCNs does not appear to occur at 
morphologically distinct fusion zones (157). In summary, actin filaments may 
have several roles in exocytosis, including functions in LDCV trafficking and 
tethering, acting as a barrier to fusion, and transporting membrane fusion 
machinery (238). 
 Exocytosis of vesicles is a multi-step process, involving a network of 
interacting proteins at various locations (Fig. 1A), including on the LDCVs 
themselves and at the active zones of the plasma membrane, where 
membrane fusion occurs (229). Exocytosis of both LDCVs and synaptic 
vesicles involves the soluble N-ethylmaleimide-sensitive factor attachment 
receptor (SNARE) complex, which opens the fusion pore and catalyzes the 
fusion of the vesicle membrane with the plasma membrane, resulting in the 
release of its cargo into the extracellular space. There is also evidence for the 
involvement of SNARE proteins in dendritic release, much of the data coming 
from work on dopamine cells in the substantia nigra (12, 180, 254) (see 
below). Studies of other brain regions, including the hippocampus (132, 133), 
olfactory bulb (140), cerebellum (59) and neocortex (266) also indicate the 
requirement for SNARE variants in dendritic transmitter release. 
 Clostridial neurotoxins, after binding to peripheral neurons and 
undergoing reverse axonal transport, are the precursors of zinc proteinases 
that specifically cleave components of the SNARE complex. Tetanus toxin 
(TeTX) cleaves VAMP-2 (synaptobrevin 2, an intrinsic protein component of 
LDCV membranes and part of the SNARE complex). Sensitivity of 
somatodendritic release to TeTX has been described in isolated MCNs (53), 
implying involvement of VAMP-2 in dendritic release of oxytocin and 
vasopressin, as well as in transmitter release at synapses. Although many 
SNARE proteins have already been identified in the terminals of the posterior 
pituitary (96, 263), immunofluorescence studies have failed to detect core 
proteins, including VAMP-2 and SNAP-25, in the somata and dendrites of the 
SON. Somatodendritic peptide release from MCNs thus appears to occur 
without all of the machinery that is needed for regulated exocytosis in other 
cell types (235), but it is probable that the functions of the missing protein 
components are fulfilled by other variants. 
 
Does somatodendritic dopamine release occur by exocytosis?  
  Studies of the subcellular anatomical characteristics of dopamine 
neurons have raised questions about the mechanism and regulation of 
somatodendritic dopamine release.  
First, dopamine axons in the striatum contain abundant clusters of 
vesicles near the plasma membrane at presumed release sites (171, 185). 
Although early anatomical studies also observed vesicle clusters in dopamine 
somata and dendrites within the SNc (253), subsequent studies, including 
those using immunogold labeling of VMAT2 profiles, concluded that SNc 
dopamine somata generally lack such clusters (170). as do dopamine 
dendrites within the substantia nigra pars reticulata (SNr) (79, 249, 253). 
Nonetheless, evidence for exocytosis is provided by reports of quantal 
dopamine release from somata in the SNc, the estimated quantal size being 
14,000 molecules per vesicle (91), which is of similar magnitude to that seen 
in adrenal chromaffin granules (117) and axonal varicosities of dopamine 
neurons in culture (188, 219).  
Second, although some dopamine is stored in small electron-lucent 
vesicles (ELVs) and in LDCVs (170), somatic dopamine in both SNc and VTA 
appears to be mainly stored in 'tubulovesicles', saccules of smooth 
endoplasmic reticulum (SER) that express VMAT2 (Fig. 1B) (170, 253). In 
addition, VMAT2 can be visualized on the outer membranes of organelles that 
may be involved in recycling vesicular membrane proteins (170). Whether 
dopamine is released directly from tubulovesicles or whether they can provide 
a rapid on-demand source of vesicles for release is not currently known. 
Inhibitors of VMAT2 block dopamine release, confirming the importance of 
dopamine uptake and storage, but not necessarily the involvement of 
exocytosis per se. Third, although dendro-dendritic dopamine synapses are 
present in both SNc and VTA, they are also rare (79, 170, 249, 253), and are 
virtually absent from the dopamine-dendrite rich SNr (79).  
 Studies using botulinum toxins to target specific SNARE proteins 
suggest that somatodendritic dopamine release occurs primarily by exocytosis 
(13, 70, 180). However, immunohistochemical studies indicate that TH-
positive somata and dendrites in the substantia nigra lack some typical 
intrinsic vesicle membrane proteins, including synaptophysin, the sv2a and 
sv2b isoforms of synaptic vesicle protein 2, and the Ca2+-sensors 
synaptotagmin 1 and 2 (254). These findings are consistent with the relative 
absence of conventional synaptic vesicles in dopamine neurons. Moreover, 
several of the conventional SNARE proteins involved in vesicle docking, 
including the vesicle membrane protein VAMP-1 (synaptobrevin 1) and the 
plasma membrane protein syntaxin 1a, are also absent. On the other hand, 
SNAP-25 and some non-conventional SNARE protein isoforms, including 
VAMP-2 and the plasma membrane protein syntaxin 3b, are expressed 
throughout dopamine somata (143, 254).  
Overall, the molecular organization involved in dopamine release in the 
SNc appears to differ markedly from that of conventional synaptic vesicular 
release, with the SNARE triad having the unusual composition of VAMP-2, 
SNAP25 and syntaxin 3b (Fig. 1B). Importantly, although dopamine somata 
and dendrites in the SNc lack synaptotagmin 1 and 2 (143, 254), which are 
low-affinity isoforms of the vesicular Ca2+-sensors found at fast synapses 
(259), they do possess two isoforms with higher Ca2+-affinity, namely 
synaptotagmin 4 and 7 (143), which may play a role in the high Ca2+ 
sensitivity of somatodendritic release (28). It should be noted, however, that 
the dopamine neurons express mRNA for synaptotagmin 1, presumably 
because synaptotagmin 1 is involved in axonal dopamine release in the 
striatum. Indeed, consistent with the notion that synaptotagmin 4 and 7, but 
not synaptotagmin 1, are involved in somatodendritic dopamine release, 
down-regulation with siRNA of synaptotagmin 4 and 7, but not of 
synaptotagmin 1, decreases dopamine release from cultured midbrain 
neurons (143).  
 Despite the presence of SNARE complex components (syntaxin 3b, 
SNAP-25 and VAMP2) throughout dopamine somata and dendrites, levels of 
VMAT2 and V-ATPase, the vacuolar-type H+-translocating ATPase that 
generates the transmembrane electrochemical proton potential gradient 
required for active amine uptake through VMAT2, decrease from somata to 
distal dendrites of dopamine neurons (254). This suggests that release and 
storage mechanisms for dopamine may differ between cell bodies and 
proximal dendrites in the SNc and those in distal dendrites in the SNr. As 
discussed further below, the regulation of dopamine release by intracellular 
Ca2+ stores may also differ between these locations: dopamine dendrites in 
the SNr have low levels of the sarco/endoplasmic reticulum Ca2+-ATPase 
(SERCA), which translocates cytosolic Ca2+ into the ER, and also low levels 
of regulatory inositol 1,4,5-triphosphate receptors (IP3Rs) and ryanodine 
receptors (RyRs) in the ER (184).  
 These data, together with the limited number of dendro-dendritic 
synapses and the small population of 'classical' LDCVs (79, 145, 170, 249, 
253), suggest that some somatodendritic dopamine release might occur by 
mechanisms other than exocytosis, including release from the cytoplasmic 
pool by reverse transport through the plasma membrane DAT (60, 63, 79, 
170, 177). Cytoplasmic dopamine concentrations are normally too low for 
DAT reversal, unless enhanced by displacement of dopamine from vesicles 
by pharmacological agents such as amphetamine (118, 230). However, 
dopamine storage in tubulovesicles introduces the possibility that dopamine 
leakage from these organelles might raise the cytoplasmic dopamine 
concentration sufficiently for DAT reversal and release into the extracellular 
space (Fig. 1B). Importantly, given that evoked increases in [DA]o are usually 
enhanced, rather than abolished, by DAT inhibitors (10, 29, 40), this cannot 
be the primary release mechanism in the SNc. Furthermore, release by direct 
transport through the plasma membrane cannot account for the observed 
quantal transmitter release in the SNc recorded by amperometry (91). In 
contrast, release from distal dendrites in the SNr is abolished by inhibition of 
DAT when stimulated by glutamate released from subthalamic nucleus 
afferents (63), and has been proposed to occur by activation of metabotropic 
glutamate receptors (mGluR1), with subsequent PKC-induced reversal of the 
DAT (63, 177).  
 
Ca2+ dependence of somatodendritic release  
 
Somatodendritic oxytocin and vasopressin release 
As described above, release of neurotransmitters from presynaptic 
terminals and of neuropeptides from neuroendocrine cells occurs by the 
ubiquitous process of Ca2+-dependent exocytosis. Like the release of oxytocin 
and vasopressin from axonal terminals in the neurohypophysis (65), dendritic 
release of these neuropeptides depends on a local increase in intracellular 
free Ca2+ concentration ([Ca2+]i) (53, 167, 215).  
 In classical synapses the patterns of neurotransmitter release depend 
critically on the spatio-dynamics of the [Ca2+]i transients (142), which are 
themselves determined by the origin of Ca2+ and its proximity to the release 
machinery, as well as by the various intracellular Ca2+ buffering mechanisms 
that control the amplitude and duration of [Ca2+]i transients. The Ca2+ that 
triggers the dendritic release of oxytocin and vasopressin from MCNs can 
originate from a number of extracellular and intracellular sources (Fig. 1A). 
 
Ca2+ channels 
  Voltage-gated Ca2+ channels (VGCCs) (65, 247) are responsible for the 
entry of much of the extracellular Ca2+ that triggers dendritic neuropeptide 
release. MCNs express several types of VGCCs (67). Despite the fact that the 
Ca2+ current carried by N-type channels is small compared to those of the 
other types of VGCC or to the whole-cell Ca2+ current in the somata of MCNs 
(94, 236), N-type channels appear to be particularly important for dendritic 
release, as release of oxytocin from SONs is most sensitive to blockade of N-
type channels, N-type channels in both in somatodendritic and in axonal 
compartments can be opened in response to the depolarization evoked by 
action potentials (65). However, some signaling molecules, including oxytocin 
and vasopressin, can trigger dendritic peptide release without increasing the 
electrical activity of the neurons, via their receptors on oxytocin and 
vasopressin neurons (71). These peptides act at their respective receptors to 
produce a cell-type specific rise in intracellular Ca2+ concentration that can 
promote transmitter release. Vasopressin-dependent vasopressin secretion 
depends on Ca2+ influx through VGCCs, particularly of the L-, N- and T-types 
(205). Similarly, Ca2+ entry, mainly through L- and N-type channels, is also the 
trigger for somatodendritic release of other transmitters, including dynorphin 
(216), dopamine (101, 143), serotonin (241) and pituitary adenylate cyclase 
activating polypeptide (PACAP) (215). 
 
NMDA receptors  
Extracellular Ca2+ can also enter neurons through Ca2+-permeable 
ionotropic glutamate receptors, including N-methyl-D-aspartate receptors 
(NMDARs). In MCNs NMDARs influence overall MCN excitability and are also 
involved in the control of burst-firing of these cells, which optimizes hormonal 
release from neurohypophysial terminals (66, 86, 162, 173). Opening of 
NMDARs results in Ca2+ entry and in large increases in dendritic [Ca2+]i in 
MCNs (218, 222), with consequent dendritic release of both oxytocin (51) and 
vasopressin (218). Consistent with this, functional NMDARs with unique 
molecular and functional properties have been found at extrasynaptic, as well 
postsynaptic, sites (113, 207) in MCNs. Extrasynaptic NMDARs are also 
coupled to other Ca2+-dependent signaling mechanisms, including voltage-
gated K+ channels and ionotropic gamma-aminobutyric acid (GABAA) 
receptors (162, 186, 187), unlike synaptic NMDARs. However it is not yet 
known whether dendritic release of neuropeptides is differentially regulated by 
synaptic versus extrasynaptic NMDARs. 
 
Intracellular Ca2+ stores 
As well as being triggered by the entry of extracellular Ca2+, dendritic 
neuropeptide release can be evoked by Ca2+ release from intracellular stores 
(Fig. 1A). An example of this is the autocrine release of oxytocin, in which 
binding of oxytocin to its receptors on oxytocin neurons causes Ca2+ to be 
released from its major intracellular store in the endoplasmic reticulum (ER) 
(107). The increase in [Ca2+]i triggers the release of oxytocin from dendrites, 
without inducing release from nerve terminals or affecting the firing of neurons 
(129). Through this autocrine mechanism, dendritic peptide release, once 
triggered, can become self-sustaining and thus long-lasting (129). Other 
agents that mobilize intracellular Ca2+ can also evoke dendritic release of 
neuropeptides. One example is thapsigargin, an inhibitor of SERCA, which 
can inhibit uptake of Ca2+ into the ER, raising cytoplasmic [Ca2+] and thereby 
triggering Ca2+-induced Ca2+ release from the ER, through ryanodine 
receptors (RyRs) (121, 129, 237). 
 
Ca2+ buffering mechanisms 
Intracellular Ca2+-buffering mechanisms influence the amplitude and 
duration of cytoplasmic Ca2+ transients. Various mechanisms of Ca2+ buffering 
and clearance mechanisms operate in MCNs, including Ca2+-translocating 
ATPases both in the ER and in plasma membranes, the mitochondrial Ca2+-
uniporter (221) and Ca2+-binding proteins such as calbindin and calretinin (50, 
148). The operation of these buffering and transport systems damps [Ca2+]i 
transients in MCNs (50, 105, 214, 222), whereas their blockade prolongs the 
transient rise in [Ca2+]i that accompanies depolarization by K+, and thereby 
enhances somatodendritic vasopressin release (105). Interestingly, the 
repertoire of Ca2+-homeostatic systems differs between the somatodendritic 
and axonal compartments of MCNs (50, 105), providing further evidence to 
support independent regulation of neuropeptide release by these two 
compartments.  
 
Ca2+-dependent priming of dendritic release 
As well as triggering the final membrane-fusion step in exocytosis, 
elevation of intracellular free [Ca2+] also primes vesicular stores of peptides 
within the dendrites, rendering them 'release-ready' and available for 
subsequent Ca2+-dependent fusion (Fig. 1A) (129). Spike activity in oxytocin 
or vasopressin neurons in vivo is not itself sufficient to trigger dendritic peptide 
release unless the stores have been primed, but agents that deplete 
intracellular Ca2+-stores, such as thapsigargin or cyclopiazonic acid (SERCA 
inhibitors), or some peptides, including oxytocin itself and alpha melanocyte-
stimulating hormone (α-MSH), consistently induce dendritic release directly 
(129, 204). It is possible that any signal that mobilizes Ca2+ from intracellular 
stores might prime dendritic secretion. Moreover, exposure to agents that 
mobilize Ca2+ from intracellular stores greatly stimulates the peptide release 
evoked by many stimuli such as electrical or osmotic stimulation and K+-
induced depolarization. In vitro, such priming persists for at least 90 min. 
During priming, neuropeptide-storing vesicles become competent to respond to 
the fusion trigger that will arrive at some point in the future, in other words, 
priming increases the size of the secretory pool available for rapid release in 
response to a future trigger of the target cell. One mechanism by which 
vesicles in MCNs leave the reserve pool and enter the release-ready pool 
(237) may be the remodeling of actin. Priming also involves the recruitment of 
VGCCs to the plasma membrane, suggesting that stimuli that increase 
secretory responsiveness on a relatively slow time scale (30-90 min) may act 
by stimulating the recruitment of N-type Ca2+ channels to release sites, where 
they potentiate the secretory response subsequent depolarizations (236). This 
priming of exocytosis appears not to require either gene transcription or de 
novo protein synthesis (234). 
 
Somatodendritic dopamine release  
In the very first report of somatodendritic dopamine release, Geffen 
and colleagues proposed that, in a manner similar to axonal dopamine 
release, dopamine release in the SNc occurs by exocytosis of storage 
vesicles (74). However, details of the precise release mechanism remain 
incomplete. Although the somata and dendrites of SNc dopamine neurons 
lack conventional synaptic structures, dopamine release from the 
somatodendritic compartment occurs by Ca2+-dependent exocytosis. 
Moreover, somatodendritic dopamine release requires Na+-dependent action 
potentials (29, 210), and is prevented by inhibitors of VMAT2 (10, 83, 198). 
However as mentioned above, the effect of VMAT2 inhibitors alone does not 
confirm that dopamine release occurs from conventional storage vesicles, as 
VMAT2 is also expressed by other subcellular organelles in dopamine 
neurons (170). 
 
Ca2+ entry  
The requirement for extracellular Ca2+ in somatodendritic dopamine 
release has become a matter of debate. Although somatodendritic release is 
prevented by the removal of extracellular Ca2+ (in Ca2+-free media containing 
the Ca2+-chelator EGTA) or by blocking Ca2+-channels in the plasma 
membrane with Cd2+ (28, 184, 196, 198), release can still occur at low 
(submillimolar) extracellular Ca2+ concentrations ([Ca2+]o) that do not trigger 
detectable axonal dopamine release, at least in guinea-pig SNc. Indeed, in 
studies using FCV to detect single-pulse evoked increases in [DA]o in guinea 
pig midbrain and striatal slices (28), the [Ca2+]o required for half-maximal 
release (EC50) is markedly lower in the SNc (0.3 mM) than in the CPu (2.3 
mM); similar differences were observed in the VTA versus NAc shell. It should 
be noted that although these studies were done in the presence of glutamate 
and GABA receptor antagonists, it is possible that EC50 values for the Ca2+ 
dependence for striatal dopamine release could be influenced by powerful 
regulation through ACh acting at nAChRs. However, when nAChRs are 
blocked the EC50 for calcium dependence in the CPu is remarkably similar 
(1.9 mM) (18). Furthermore, unlike in the striatum where axonal dopamine 
release is abolished by a cocktail of VGCC blockers, somatodendritic 
dopamine release in the SNc persists in the presence of these blockers (11, 
14, 27, 29, 60, 70, 85). The resistance of release to VGCC blockers 
presumably reflects the incomplete blockade of these channels, along with the 
minimal cytoplasmic Ca2+ concentration required to trigger exocytosis via the 
high Ca2+-sensitivity synaptotagmin isoforms involved in fusion. 
Somatodendritic dopamine release is therefore only weakly dependent on 
[Ca2+]o and Ca2+ entry. Interestingly, the dependence on [Ca2+]o for 
somatodendritic dopamine release has been reported to be stronger in rat and 
mouse than in guinea pig (38, 69).   
Which VGCCs are required for Ca2+ entry in somatodendritic dopamine 
release? N- and P/Q-type, but not L-type, channels appear to be involved in 
basal somatodendritic dopamine release measured by RIA in mesencephalic 
cultures (143). L- and T-type channels, but not N- or P/Q-type channels, are 
involved in K+-evoked dopamine release in the same preparation (60), as well 
as in K+-induced dopamine release detected by amperometry in dissociated 
dopamine cells (102). Therefore, the VGCC types involved in providing Ca2+ 
entry to trigger somatodendritic dopamine release appear to depend on the 
experimental conditions, including the species studied, the type of preparation 
and the stimulation procedure employed. These factors all contribute to the 
complexity of elucidating the precise mechanisms involved in somatodendritic 
dopamine release and its regulation. 
 
Intracellular Ca2+ stores  
The ability to detect evoked somatodendritic dopamine release with 
nominally zero [Ca2+]o raises the possibility that there may be mechanisms by 
which small increases in [Ca2+]i are amplified. An obvious mechanism is Ca2+-
induced Ca2+ release from intracellular ER stores (129, 184, 242), as 
discussed above for oxytocin and vasopressin. Within neurons, the ER forms 
a large network extending from the soma to dendrites and dendritic spines, 
and to axons and presynaptic release sites (244). In SNc dopamine neurons, 
this system propagates Ca2+ release from somatic ER stores to dendrites 
(34).  
Immunohistochemical studies have identified ER membrane proteins 
associated with Ca2+ mobilization from ER stores in SNc somata and proximal 
dendrites, including SERCA-2 and inositol tris-phosphate receptors (IP3R) and 
RyRs (184), which are ligand-gated Ca2+-channels. Each of these facilitate 
somatodendritic dopamine release evoked in the SNc by local pulse-train 
stimulation and detected by FCV (184). In dopamine neurons, RyRs assemble 
in clusters that are closely apposed to the plasma membrane, a location that 
maximizes their activation with the entry of extracellular Ca2+ through VGCCs 
(Fig. 1B). This enables somatodendritic dopamine release to be amplified at 
physiological [Ca2+]o. This amplification, however, is not necessary when Ca2+ 
entry is sufficiently large, as occurs with higher [Ca2+]o. In contrast, facilitation 
of SNc dopamine release by IP3Rs does not necessarily require Ca2+ entry 
through VGCCs but can occur downstream from metabotropic receptors, 
including mGluR1 (Fig. 1B) (184).  
    The role of intracellular Ca2+ stores in amplifying somatodendritic 
dopamine release is complex, and also can vary with the experimental 
conditions and rodent species used (38, 69, 143). Moreover, whether 
intracellular Ca2+ stores contribute to release in the VTA is not yet known. 
Exocytosis involves several Ca2+-dependent steps with proteins that exhibit 
different Ca2+ sensitivities. The final fusion event may require a very rapid 
elevation in [Ca2+]i close to the secretory vesicle to trigger release, whereas a 
slower, less localized increase in [Ca2+]i could enhance priming of secretory 
vesicles, as seen in the release of oxytocin from the dendrites of hypothalamic 
neurons (129), discussed above. Although most evidence suggests that 
dopamine release in the SN or the VTA is not primed by the SERCA inhibitor 
thapsigargin, the possible involvement of other intracellular Ca2+ stores 
remains unknown (12). Whether the differential expression of RyR at sites 
close to the plasma membrane and the cytoplasmic location of IP3R reflect 
these different functions also remains unresolved. 
 
Is somatodendritic release triggered by action potentials? 
 Action potentials are usually initiated at the junction between cell body 
and axon, the axon hillock. In the classical model of synaptic neurotransmitter 
release, the action potential is propagated down the axon to its terminal where 
it opens VGCCs, resulting in the fusion of synaptic vesicles with the pre-
synaptic plasma membrane. However, an action potential can travel in any 
direction from its point of initiation, and into dendrites if the electrical 
properties of the dendrite support this, as is the case in many neurons (39, 
227).  
    Exocytotic release of vasopressin and oxytocin from axonal terminals 
in the posterior pituitary gland is linked to electrical activity in the somata and 
is produced by the opening of VGCCs following depolarization of the terminals 
by invading action potentials (65). At classical fast, glutamatergic synapses, 
the available stores of small ELVs are maintained by endocytotic membrane 
recycling and are quickly reacidified by the V-type H+-ATPase and re-filled 
with neurotransmitter by secondary active transport mediated by H+-linked 
antiporters (190). However, unlike small neurotransmitters, neuropeptides are 
not taken up and repackaged after release – they must be synthesized in the 
rough ER and concentrated in LDCVs in the soma. Compared to ELVs, 
LDCVs require a more sustained increase in [Ca2+]i to trigger exocytosis. 
Consequently, LDCVs have longer latencies to release and require stronger 
stimulation for exocytosis, for example bursts of electrical activity. LDCVs also 
differ from ELVs in that the associated variants of synaptotagmin, the Ca2+-
sensor that triggers release, have a higher affinity for Ca2+, as discussed 
above for dopamine. Consequently it is not necessary for LDCVs to be 
located close to membrane Ca2+ channels to receive a Ca2+ pulse sufficient to 
produce exocytosis, and synaptic specializations are not necessary (2, 6, 135, 
136, 208). 
In many neurons, the properties of the dendritic membranes support 
the propagation of action potentials (227). However, dendritic release of 
vasopressin and oxytocin in MCNs can occur independently of action 
potentials (121, 129), even though action potentials can propagate into the 
dendrites (5). Accordingly, neuropeptide release from dendrites is not linked 
to release from terminals within the same neurons, and this uncoupling seems 
to be both stimulus-dependent and peptide-specific (127). An example of this 
is provided by the effects of alpha melanocyte-stimulating hormone (α-MSH): 
binding of α-MSH to melanocortin 4 receptors on oxytocin cells releases Ca2+ 
from intracellular stores, stimulating dendritic oxytocin release, but inhibits the 
electrical activity of the cell and so inhibits oxytocin release into the periphery 
(204). Dissociation of dendritic and axonal release patterns is also seen in the 
effects of increased plasma osmolality. Systemic hypertonic saline injection 
immediately increases vasopressin release from axon terminals, but dendritic 
release of vasopressin in the SON starts an hour later, when peripheral 
release is subsiding. In this case there is a separation in time between 
transmitter release from dendrites and terminals within the same neurons 
(124).  
In SNc dopamine neurons, the axon initial segment arises from a 
proximal dendrite rather than from the cell body; action potentials originate in 
the dendritic tree and single action potentials back-propagate into dendrites 
(82). However, during burst-firing of these neurons, and particularly if 
dopamine D2 receptors are activated, back-propagation of action potentials 
may not occur (75), suggesting that dopamine can influence the spread of 
action potentials, thereby down-regulating its own release from dendrites. 
Thus, burst-patterned firing, which promotes dopamine release from axon 
terminals, does not necessarily promote dendritic release (78). Consequently, 
dopamine release from distal dendrites is likely to be semi-independent of the 
electrical activity of the neuron. As mentioned above, dopamine release from 
distal dendrites has been proposed to be triggered through local glutamatergic 
activation of mGluRs (177). Interestingly, serotonin neurons in the dorsal 
raphe nucleus also exhibit somatodendritic release. Action potentials in these 
neurons also do not back-propagate very far; however, local activation of 
NMDARs can lead to dendritic release in the absence of action potentials 
(52). This is yet another example of the dissociation of dendritic release of 
monoamines from action-potential-dependent axonal release.  
 
Modulation of somatodendritic release by synaptic inputs 
 
Vasopressin and oxytocin 
    Vasopressin (and in the rat, oxytocin) is involved in the control of 
plasma electrolyte balance. Systemic injection of hypertonic saline stimulates 
vasopressin and oxytocin release from axon terminals in the neural lobe and 
from dendrites within the SON. Vasopressin neurons respond directly to the 
osmotic pressure of their environment (137, 176), but systemic osmotic stimuli 
also activate central receptors on cells that project, directly or indirectly, to the 
SON and PVN, including afferent neural pathways from the rostral forebrain 
anterior 3rd ventricle region (AV3V). The response to systemic osmotic 
stimulation is blocked by tetrodotoxin, which blocks voltage-gated Na+-
channels, and by lesions of the AV3V, suggesting that somatodendritic 
release is part of a cascade of events initiated by osmotic activation of 
synaptic pathways, rather than by the direct effect of hyperosmolarity on the 
MCNs (122, 123).  
The afferent pathways from the AV3V include an inhibitory GABA 
component (174) and excitatory components mediated by amino acids and 
several peptides, including angiotensin II (92). Intracerebroventricular (icv) 
administration of angiotensin increases both systemic and somatodendritic 
vasopressin release within the SON and PVN (152). While somatodendritic 
release is unaffected by retrodialysis of the GABA agonist muscimol into the 
SON, the GABAAR antagonist bicuculline increases somatodendritic release 
(109), suggesting tonic inhibition by endogenous GABA. Furthermore 
glutamate stimulates dose-dependent release of angiotensin II from isolated 
fragments of magnocellular dendrites (158) and also increases 
somatodendritic release when retrodialysed into the SON, whereas kynurenic 
acid, a glutamate antagonist, is inhibitory (109). 
 Somatodendritic release of vasopressin following acute osmotic 
stimulation is inhibited by salt loading but not by water deprivation, while the 
systemic response is unaffected (130), suggesting that somatodendritic 
release is regulated by afferent inputs from both osmo- and baro-receptors. 
The control of central peptide release by volume and pressor stimuli is also 
revealed by studies of hemorrhage and baroreceptor denervation; 
concentrations of vasopressin both in the plasma and in the PVN increase 
markedly in response to hemorrhage (179). Hemorrhage-induced decrease of 
arterial blood pressure stimulates vasopressin secretion through inhibition of 
baroreceptors and activation of chemoreceptors in the aortic arch and carotid 
body, while sinoaortic baroreceptor denervation increases the osmotically-
induced release of vasopressin and oxytocin from the posterior pituitary (159) 
and also increases somatodendritic vasopressin release stimulated by direct 
or peripheral hypertonic saline stimulation (22).  
 Systemic oxytocin release increases during parturition and lactation, in 
parallel with increased electrical activity involving the synchronous burst firing 
of oxytocin neurons. That oxytocin, but not vasopressin, is released within the 
SON and PVN in response to suckling has been demonstrated in push-pull 
perfusion studies in anaesthetized lactating rats (19) and microdialysis studies 
in conscious parturient and lactating animals (22). Somatodendritic suckling- 
or parturition-induced oxytocin release is inhibited by oxytocin antagonists 
infused into the SON, suggesting the receptor-mediated autoregulation of 
oxytocin release (163, 164).  
 The systemic secretion of oxytocin during suckling is also subject to 
noradrenergic regulation, arising mainly from the brainstem. Suckling 
increases both noradrenaline turnover and local oxytocin levels within the 
SON (47), and phentolamine, an -adrenergic antagonist, blocks oxytocin 
release into the SON and PVN during suckling, indicating that suckling 
stimulates noradrenaline release, with subsequent stimulation of 
somatodendritic oxytocin release through the action of -adrenergic receptors 
(8).  
 Systemic and somatodendritic peptide release are also controlled by 
other neurotransmitters released by nerve fibers terminating in the 
hypothalamic nuclei. GABA and glutamate have already been discussed. 
Acetylcholine is also involved in regulating systemic vasopressin release 
(217), and also stimulates somatodendritic vasopressin release in 
hypothalamic explants (excluding axon terminals) (138, 178). Both 
somatodendritic and systemic release of oxytocin appear to be regulated by 
noradrenaline (165), since systemic administration of cholecystokinin (CCK), 
which acts via the vagus nerve to excite the A2 noradrenergic brainstem 
projection to magnocellular oxytocin neurons (243), stimulates release. CCK 
may also directly regulate somatodendritic peptide release; intra-SON 
administration of CCK increases somatodendritic oxytocin and vasopressin 
levels (165), and also the expression of Fos in SON neurons (125).  
 Pituitary adenylate cyclase activating polypeptide (PACAP) receptor 
mRNA and PACAP-like immunoreactivity are present within the SON and 
PVN (161) and PACAP appears to participate in the regulation of the MCNs 
by opening VGCCs and increasing cytoplasmic [Ca2+], thereby stimulating the 
somatodendritic release of vasopressin in vitro (215). 
Dendritic oxytocin release from MCNs is inhibited by endogenous 
opioids in ovariectomized (87) and late-pregnant rats, although this inhibition 
does not occur during parturition (58, 163). In addition, in morphine-
dependent rats, the opioid antagonist naloxone, introduced into the SON 
either by systemic injection or by retrodialysis, increases somatodendritic 
oxytocin release (20, 203). This 'morphine withdrawal excitation' also involves 
somatodendritic oxytocin, the release of which is increased under these 
conditions, while icv administration of an oxytocin antagonist reduces this 
increase (20).  
    During late pregnancy, sex steroids promote oxytocin synthesis and 
storage within the dendrites of the MCNs (156), and steroids have also been 
proposed to exert direct, rapid, non-genomic effects on neurons (232).  
 
Dopamine  
    Synaptic input to midbrain dopamine neurons comes predominantly 
from glutamate and GABA, with GABAergic input dominating in the SNc and 
glutamatergic input dominating in the VTA (154, 197). Consequently, the net 
influence of excitatory versus inhibitory regulation of dopamine neurons differs 
between the SNc and VTA. In ex vivo midbrain slices, somatodendritic 
dopamine release evoked by a single stimulus pulse is unaltered by ionotropic 
glutamate or GABA receptor antagonists (27), suggesting the absence of 
tonic regulation by these transmitters in slices. However, during stimulation by 
multiple pulses, regulation by concurrently released glutamate and GABA is 
seen in both the SNc and VTA (30). In the SNc, dopamine release evoked by 
local pulse-train stimulation is inhibited by concurrently released glutamate 
acting on AMPA- and NMDA-receptors. This inhibition is prevented by GABA 
receptor antagonists, which is consistent with anatomical data showing 
AMPARs on inhibitory input to the SNc (182, 260), (30). In contrast, the 
increase in dopamine release produced by NMDA-receptor antagonists during 
pulse-train stimulation is unaffected by a cocktail of GABA receptor 
antagonists, suggesting the involvement of another inhibitory mediator. One 
possible candidate is endogenously generated H2O2, which has been shown 
to inhibit dopamine release in the SNc (26) and may be generated 
downstream from NMDAR activation.  
In the VTA, pulse-train evoked dopamine release is unaffected by 
blocking GABAA-, GABAB- or AMPA-receptors. By contrast, NMDA-receptor 
blockade suppresses evoked [DA]o, consistent with a glutamate-dependent 
facilitation of dopamine release (30). Importantly, however, blockers of either 
AMPA- or NMDA-receptors decrease evoked dopamine release when applied 
in the presence of GABA-receptor antagonists, thereby unmasking the 
conventional direct excitatory effect of glutamate input to VTA dopamine 
neurons.  
    Regulation by glutamate of somatodendritic dopamine release in the 
SNc also occurs through the metabotropic, G-protein coupled receptor 
mGluR1 (184). mGluR1α is highly expressed in dopamine neurons and, as 
described above, mGluR1 activation produces IP3R-mediated Ca2+ release 
from ER stores, which facilitates evoked dopamine release. However, with 
large increases in intracellular Ca2+, inhibition of dopamine neuron excitability 
and consequently dopamine release may occur from activation of Ca2+-
activated K+ channels (64, 153). Therefore, the net effect of dopamine release 
regulation by mGluR1s will depend on exogenous mGluR1 agonist 
concentration or on stimulus intensity for endogenous glutamate release (48, 
184). As already noted, activation of mGluR1s can also facilitate dendritic 
dopamine release in the SNr, possibly from elevated dopamine levels in the 
cytoplasm and subsequent DAT reversal (177).  
 
Possible role of co-released glutamate and GABA 
    The increasing recognition that dopamine neurons co-release multiple 
transmitters including glutamate and GABA provides a novel concept in the 
idea of “autoreceptor” regulation. Initial studies using cultured dopamine 
neurons established that they can both synthesize and release glutamate (36, 
55). In support of this, subsequent optogenetic methods using selective 
expression of channelrhodopsin (ChR2) in dopamine neurons have 
demonstrated that glutamate released from dopamine axons produces 
glutamate receptor-dependent excitatory post-synaptic currents in striatal 
neurons in slices (35, 106, 225, 228, 231, 240) and mediates behavioral 
effects in vivo (16). Similar approaches have been used to show co-release of 
GABA from dopamine axons; although these neurons synthesize GABA using 
a non-conventional enzyme, aldehyde dehydrogenase 1a1 (100), and they 
can also obtain GABA by uptake from the extracellular space (225, 240). 
Thus, if also co-released with dopamine from somata or dendrites, glutamate 
and/or GABA could autoregulate somatodendritic dopamine release. This 
possibility is supported by the presence of vesicular glutamate transporters 
(vGluT2) in VTA dopamine neurons (55, 84), and co-released GABA appears 
to be accumulated in secretory vesicles through VMAT2 (240), which is 
present in all midbrain dopamine cell bodies and proximal dendrites (170). 
 
Actions of dendritically released oxytocin, vasopressin and dopamine 
  
Autocrine effects  
    Dendritically released neurotransmitters exhibit autocrine effects on the 
neurons from which they are released, and also affect surrounding neurons 
and glia. These effects can change both the inputs to cells and the cellular 
response to these inputs. A good example of this occurs in oxytocin cells, in 
which dendritically released oxytocin enhances the milk ejection reflex, as 
described below.  
  More commonly, somatodendritic release is auto-inhibitory and thus 
self-limiting. Vasopressin neurons discharge in a characteristic phasic pattern 
that maximizes stimulus-secretion coupling at the nerve terminals, but this 
activity is modified by the inhibitory autocrine effects of vasopressin released 
from dendrites. Like oxytocin, vasopressin can also facilitate its own dendritic 
release (258), which may explain the temporal separation of peripheral and 
central release of vasopressin following a hyperosmotic stimulus. Osmotic 
stimulation is followed immediately by systemic secretion of vasopressin, 
whereas dendritic release is delayed and the response prolonged (124). 
Increase of extraneuronal vasopressin concentrations by retrodialysis inhibits 
vasopressin neurons, reducing their firing rate (126). Thus, dendritic 
vasopressin release may stimulate vasopressin release from adjacent 
dendrites until the local external concentration reaches a threshold sufficient 
to hyperpolarize the neuron or else to modulate inhibitory inputs, thereby 
limiting the extent of systemic vasopressin secretion following osmotic stimuli 
or volume depletion. 
Understanding of these autocrine effects is further complicated by the 
fact that within a single LCDV, several other peptides have been co-localized 
with either vasopressin or oxytocin. For example, the endogenous opioid 
dynorphin is co-localized with vasopressin in the same vesicles (250) and 
dendritic vasopressin release will therefore be accompanied by the release of 
dynorphin to provide feedback inhibition of vasopressin cell activity (21). In 
addition many other neuropeptides, such as galanin, apelin, PACAP and 
secretin, are synthesized in MCNs (54, 72, 77, 112). Accompanying receptor 
expression for these peptides on MCNs provides mechanisms for autocrine 
feedback regulation by these co-released neuropeptides (19). 
 Autocrine effects of somatodendritic dopamine release are central to 
the consequences of this process. Locally released dopamine binds to 
inhibitory D2 autoreceptors on dopamine neurons in the SNc and VTA, and 
thereby regulates the rate and pattern of firing of dopamine neurons (10, 73, 
75, 191, 265), which ultimately influences the level and pattern of axonal 
dopamine release in CPu and NAc (211). Somatodendritic dopamine release 
in SNc and VTA is also controlled by local feedback via D2 autoreceptors 
(41).  
 
 
Paracrine effects  
    Exogenously applied or endogenously released oxytocin also acts on 
afferent nerve endings. The SON does not contain presynaptic oxytocin 
receptors, suggesting that this paracrine action is indirect. One indirect 
mechanism involves oxytocin-dependent endocannabinoid release from 
oxytocin neurons (104, 175), mediated by the action of dendritically released 
oxytocin on oxytocin receptors, release of Ca2+ from intracellular stores and 
consequent ‘on-demand’ synthesis of endocannabinoids. Endocannabinoids 
are arachidonate-based lipids that are hydrophobic enough to diffuse 
passively through plasma membranes; their binding to presynaptic 
cannabinoid receptors (CB1) inhibits both GABAergic and glutamatergic 
afferents onto MCNs. Indeed, CB1 receptors have been found using 
immunohistochemistry on both excitatory and inhibitory axon terminals that 
innervate dendrites in the SON. In SON slices, cannabinoid agonists 
presynaptically inhibit spontaneous excitatory and inhibitory postsynaptic 
currents.  
 The milk-ejection reflex during suckling provides an interesting 
example of local paracrine control by oxytocin. Oxytocin neurons are 
continuously active under basal conditions but during parturition and in 
response to suckling in lactating animals, discharge brief, intense bursts of 
action potentials. These bursts release large boluses of oxytocin into the 
circulation, producing intense contractions of the pregnant uterus or milk 
ejection from the mammary glands. The bursts are blocked by administration 
of oxytocin antagonists into the SON, and facilitated by oxytocin agonists 
(108). Dendritic release of oxytocin is up-regulated during parturition and in 
lactation, and has an essential role in the generation of these intermittent 
synchronized bursts (201). Its effects are not restricted to the cell of origin, but 
are also exerted on the dendrites of other oxytocin cells, possibly to facilitate 
homotypic interactions 
 Dendritically-released vasopressin modulates the activity of 
neighboring presympathetic neurons within the PVN (218), providing another 
example of a long-distance, paracrine action of dendritically-released 
neuropeptides. Activity-dependent dendritic release of vasopressin from 
MCNs concomitant increases the firing activity of neurons projecting from the 
PVN to the rostroventrolateral medulla. This interpopulation crosstalk involves 
extracellular diffusion of released vasopressin to V1a receptors in 
presympathetic neurons. Consequently, unlike conventional synaptic 
transmission, the efficiency and strength of this diffuse paracrine action of 
vasopressin depends on the extracellular vasopressin concentration, which in 
turn depends on the average activity of the entire vasopressin neuron 
population. It also depends on the half-life of vasopressin in the extracellular 
space, as well as on the ability of vasopressin to reach relatively distant 
targets by diffusion (e.g. the tortuosity of the extracellular space). These 
examples illustrate the importance of dendritic release of vasopressin in the 
ability of the PVN to control the activity of distinct populations of neurons, and 
thus, to produce a multimodal homeostatic response (218, 220).  
 Given the structural characteristics of midbrain SNc and VTA dopamine 
neurons, somatodendritic dopamine release is likely to be at least partly non-
synaptic. Moreover, dopamine receptors and reuptake transporters on 
dopamine cell bodies and dendrites are largely extrasynaptic (171, 172, 213, 
261), as are D1 receptors on non-dopaminergic terminals in these regions 
(23, 261). Thus, somatodendritically released dopamine must act through 
volume transmission via the extracellular fluid (194, 195). Extracellular 
dopamine concentrations are in turn regulated by diffusion, by uptake through 
the DAT and by the (probably negligible) effects of enzyme-catalysed 
degradation (43, 195). Diffusion measurements in ex vivo guinea pig midbrain 
slices reveal that the extracellular volume fraction in the SNc, SNr and VTA is 
~50% larger that that in forebrain structures, including the striatum (43), which 
would lead to lower extracellular concentrations in midbrain than forebrain for 
a given number of molecules released. Of course, net [DA]o is also influenced 
by other regulators, especially uptake, which is greater in the striatum than in 
the midbrain, so that absolute concentrations in these regions do not differ as 
much as predicted by diffusion characteristics alone (195). Interestingly, DAT 
activity is greater in SNc than VTA, as well, leading to greater effects of DAT 
inhibitors on evoked increase in [DA]o in SNc than in VTA (40, 43).  
    In contrast to evidence for diffusion-based volume transmission of 
dopamine in the SNc and VTA from anatomical and voltammetric studies, 
evaluation of evoked D2ICs in dopamine neurons suggests that the actions of 
dopamine are not only largely diffusion-independent, but also synaptic (9, 10, 
38). These conclusions are based on several observations. First, the 
concentration of exogenous dopamine required to induce D2ICs of similar 
magnitude to those produced by endogenously released dopamine is in the 
micromolar range. This is in contrast to the nanomolar concentrations 
expected for D2 autoreceptors in the high-affinity state. Given that the 
external dopamine concentration declines sharply with distance from a site of 
release (38, 44, 195), an interpretation of this result is that the dopamine 
detected by D2 receptors is immediately post-synaptic, or at least peri-
synaptic. Synaptic dopamine release does occur in the VTA, given the 
presence of axon collaterals (7, 28). Second, the time-course of evoked 
D2ICs is relatively constant across stimulations, as might be expected for a 
postsynaptic response. However, the kinetics of the G-protein coupled, 
inwardly-rectifying K+ (GIRK) channel activated by dopamine are likely to be 
the rate-limiting factor in this autoreceptor-mediated process. Indeed, 
modeling studies of quantal dopamine release indicate that the peak 
concentration is reached ~10 ms after a release event, even at a distance of 5 
μm from the release site (43, 44, 195), whereas the D2 IPSC peak occurs 
several hundred ms after stimulation (38, 68). Thus, the debate about 
synaptic transmission vs. volume transmission for somatodendritic release of 
dopamine remains open (68, 195).  
 
Functional roles for somatodendritic oxytocin, vasopressin and 
dopamine and other diffusible messengers in the brain 
    Oxytocin and vasopressin exert specific behavioral effects: oxytocin is 
involved in maternal behavior and social bonding, while vasopressin has 
actions in the brain that affect social recognition and aggression (88, 168, 
224). The sites at which these behavioral effects are exerted show, in some 
cases, high levels of receptor expression but little innervation by peptide-
containing projections. Could dendritically released peptides exert long-lasting 
behavioral effects by acting on distant targets within the brain? Similar 
changes in neuropeptide concentrations often occur at widely separated sites, 
even though the absolute values vary between sites (127). Dendritic peptide 
release is not targeted specifically to synapses, but peptides may travel to 
their targets by bulk flow through the extracellular fluid and cerebrospinal fluid. 
The half-life of oxytocin in the CSF is about 20 min (144), in contrast with the 
typically subsecond lifetime of dopamine, which limits the range of its action 
after both axonal and somatodendritic release (38, 44, 195).  
Somatodendritic dopamine release also plays a role in animal 
behavior, including motor activity. The action of dendritically released 
dopamine on D1 dopamine receptors in the terminals of the striatonigral direct 
pathway enhances GABA release from axons in the SNr, thereby amplifying 
inhibition of the principal cells of the SNr (149, 192, 239). Through these 
pathways, somatodendritic, as well as axonal dopamine release regulates 
motor behavior (3, 15, 45, 56, 141, 200, 212, 233).  
    The paracrine or hormone-like actions of neuropeptides and dopamine 
can enable signaling between entire populations of neurons, some of which 
may be relatively distant from each other. Thus these transmitters act in a 
more diffuse, less spatially constrained manner – and on a longer time scale – 
than those involved in classical fast synaptic transmission. At chemical 
synapses, the “secrecy” of signal transmission is maintained by the structure 
of the synapse and by the surrounding network of reuptake transporters. In 
contrast paracrine transmission has evolved so as to maximize spillover, and 
its specificity depends only on that of the signal/receptor interactions. In 
addition to the transmitters that are the focus of this review, other biogenic 
amines and acetylcholine are released from en passant boutons on axonal 
segments (264). Extending this concept further are gaseous neurotransmitters 
such as nitric oxide and carbon monoxide (49). It is likely that all of these 
molecules transmit chemical signals not simply from one cell to another, but 
from one population of neurons to another (115, 116, 127), while maintaining 
signal specificity by actions at transmitter-specific receptors.  
 
Conclusions 
Somatodendritic oxytocin and vasopressin release from hypothalamic 
neurons provides paracrine signals that are critical in several key 
physiological events, including birth, milk let-down and social bonding. 
Somatodendritic release and volume transmission of neuropeptides 
represents a form of hormonal action. These neurohormones can act in a 
temporally coherent way at discrete brain sites to establish and co-ordinate 
complex behaviors. 
Somatodendritic dopamine release from midbrain dopamine neurons 
provides an autocrine signal that regulates dopamine neuron activity, and thus 
contributes to axonal release regulation in target regions. Equally importantly, 
dopamine released within these cell body regions contributes to the regulation 
of release of other transmitters, including GABA and glutamate. Through 
these actions, somatodendritic dopamine release contributes to motor 
regulation, as well as to plasticity in rewards circuits, including aberrant 
plasticity in response to drugs of abuse.   
Recent studies provide evidence about the mechanism and regulation 
of somatodendritic release of oxytocin, vasopressin and dopamine, including 
underlying commonalities and differences. There is no reason to believe that 
somatodendritic release is restricted to these systems, and study of this 
process in other neuronal types is likely to be fruitful. How well we can 
understand somatodendritic release in the healthy brain necessarily 
influences how well we can harness these processes to treat disorders 
involving these pathways. The goal of future work into the somatodendritic 
release of peptides, dopamine and related molecules will be to provide this 
understanding. 
 
 
 
Figure Legend 
Figure 1: Comparison of the mechanisms of somatodendritic release of 
oxytocin and vasopressin in the hypothalamus (A) and dopamine in the 
substantia nigra (B).  
A) Neuropeptides are synthesized and packaged in the soma and stored in 
dendrites in a reserve pool (RP) containing large numbers of large dense-
cored vesicles (LDCVs) in dendrites. Depolarization-induced Ca2+ entry 
through voltage-gated calcium channels (VGCCs) stimulates peptide release 
by exocytosis of LDCVs. This requires the depolymerization of F-actin to G-
actin. Furthermore, the stimulation of G-protein coupled receptors, such as 
the oxytocin receptor, stimulates the mobilization of Ca2+ from IP3-dependent 
intracellular stores and an increase in both the number of LDCVs and N-type 
VGCCs at the plasma membrane, thus priming the exocytosis machinery for 
subsequent activity-dependent release. Although some members of the 
SNARE family are detectable by immunocytochemistry, there appears to be a 
lack of VAMP, SNAP-25 and synaptotagmin-1 in the somata-dendrites, with 
their function presumably being replaced by other SNARE proteins. TG, 
thapsigargin; CPA, cyclopiazonic acid 
B).  Features of somatodendritic dopamine release. Dopamine is synthesized 
in the intracellular compartment from tyrosine via tyrosine hydroxylase (TH).  
This process generates L-DOPA which is converted to dopamine by aromatic 
amino acid decarboxylase (AADC). Synthesized dopamine is stored in 
tubulovesicular structures that are part of the endoplasmic reticulum (ER); 
these structures are the primary site of VMAT2, the vesicular monoamine 
transporter expressed in dopamine soma and proximal dendrites. Dopamine 
dendrites contain few vesicles, but those present appear to bud from 
tubulovesicles. Somatodendritic dopamine release is action potential 
dependent.  Release also requires Ca2+ entry via VGCCs, but is amplified by 
both ryanodine receptors (RyRs) and metabotropic glutamate receptor 
(mGluR)-dependent activation of IP3Rs that release Ca2+ from intracellular ER 
stores.  Immunohistochemical evidence suggests that a novel constellation of 
SNARE proteins may be involved in the release, including SNAP-25, VAMP2, 
and syntaxin3b.  Release from dendrites has also been suggested to involved 
reversal of the dopamine transporter (DAT). Released dopamine is taken up 
and recycled via the DAT. 
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